Taken together, although PpargΔHep did not reduce the levels of plasma ALT nor steatosis, these data indicated that hepatocyte PPARγ and CD36 expressions could contribute to the upregulation of genes related to the progression of NASH. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.